Naya Biosciences, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
INVO FERTILITY, INC. has filed a Definitive Proxy Statement with the SEC, soliciting shareholder votes for upcoming matters.
INVO Fertility, Inc. calls a special meeting to ratify a new auditor, approve significant share issuances for a private placement, and dramatically increase authorized common stock, amidst ongoing financial concerns.
DEFA14A: INVO Fertility Updates Meeting, Implements Reverse Stock Split, and Clarifies Voting Standard
INVO Fertility, Inc. filed a supplement to its 2025 Annual Meeting proxy statement, confirming updated meeting details, announcing a 1-for-3 reverse stock split effective July 21, 2025, and correcting the voting standard for a proposal to increase authorized common stock.
INVO FERTILITY, INC. has filed a definitive proxy statement with the U.S. Securities and Exchange Commission under Schedule 14A.
INVO Fertility, Inc. is calling its 2025 Annual Meeting of Stockholders to vote on critical proposals including a significant increase in authorized common stock, conversion of preferred shares and debentures, and amendments to its stock incentive plan, following a strategic divestment of its NAYA TX biopharma holdings and a prior financial restatement.
NAYA Biosciences has postponed its 2024 Annual Meeting of Stockholders to April 9, 2025, and filed an amended proxy statement due to insufficient votes on special proposals.
Naya Biosciences, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.
NAYA Biosciences is seeking stockholder approval for several key proposals at its upcoming annual meeting, including increasing authorized shares and a potential reverse stock split.